Titre : Inhibiteurs de la 5-alpha réductase

Inhibiteurs de la 5-alpha réductase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cancer-Associated Fibroblasts
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de la 5-alpha réductase : Questions médicales les plus fréquentes", "headline": "Inhibiteurs de la 5-alpha réductase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteurs de la 5-alpha réductase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-15", "dateModified": "2025-04-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteurs de la 5-alpha réductase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Inhibiteurs de la synthèse des stéroïdes", "url": "https://questionsmedicales.fr/mesh/D065088", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la synthèse des stéroïdes", "code": { "@type": "MedicalCode", "code": "D065088", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.399.450.855" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la 5-alpha réductase", "alternateName": "5-alpha Reductase Inhibitors", "code": { "@type": "MedicalCode", "code": "D058891", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Francesco Del Giudice", "url": "https://questionsmedicales.fr/author/Francesco%20Del%20Giudice", "affiliation": { "@type": "Organization", "name": "Department of Urology, Sapienza University of Rome, Rome, Italy." } }, { "@type": "Person", "name": "James L Mohler", "url": "https://questionsmedicales.fr/author/James%20L%20Mohler", "affiliation": { "@type": "Organization", "name": "Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA." } }, { "@type": "Person", "name": "Thiraphat Saengmearnuparp", "url": "https://questionsmedicales.fr/author/Thiraphat%20Saengmearnuparp", "affiliation": { "@type": "Organization", "name": "Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand." } }, { "@type": "Person", "name": "Bannakij Lojanapiwat", "url": "https://questionsmedicales.fr/author/Bannakij%20Lojanapiwat", "affiliation": { "@type": "Organization", "name": "Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand." } }, { "@type": "Person", "name": "Nipon Chattipakorn", "url": "https://questionsmedicales.fr/author/Nipon%20Chattipakorn", "affiliation": { "@type": "Organization", "name": "Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.", "datePublished": "2023-03-06", "url": "https://questionsmedicales.fr/article/36890105", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.euo.2023.02.011" } }, { "@type": "ScholarlyArticle", "name": "Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance.", "datePublished": "2023-09-04", "url": "https://questionsmedicales.fr/article/37660643", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2023.115425" } }, { "@type": "ScholarlyArticle", "name": "Cancer-associated fibroblasts: tumor defenders in radiation therapy.", "datePublished": "2023-08-22", "url": "https://questionsmedicales.fr/article/37607935", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41419-023-06060-z" } }, { "@type": "ScholarlyArticle", "name": "Stromal circuits involving tumor-associated macrophages and cancer-associated fibroblasts.", "datePublished": "2023-06-05", "url": "https://questionsmedicales.fr/article/37342322", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1194642" } }, { "@type": "ScholarlyArticle", "name": "Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.", "datePublished": "2024-03-15", "url": "https://questionsmedicales.fr/article/38491511", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12967-024-05085-y" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Effets physiologiques des médicaments", "item": "https://questionsmedicales.fr/mesh/D045505" }, { "@type": "ListItem", "position": 5, "name": "Hormones, substituts d'hormones et antagonistes d'hormones", "item": "https://questionsmedicales.fr/mesh/D006730" }, { "@type": "ListItem", "position": 6, "name": "Antihormones", "item": "https://questionsmedicales.fr/mesh/D006727" }, { "@type": "ListItem", "position": 7, "name": "Inhibiteurs de la synthèse des stéroïdes", "item": "https://questionsmedicales.fr/mesh/D065088" }, { "@type": "ListItem", "position": 8, "name": "Inhibiteurs de la 5-alpha réductase", "item": "https://questionsmedicales.fr/mesh/D058891" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteurs de la 5-alpha réductase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la 5-alpha réductase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteurs de la 5-alpha réductase", "description": "Comment diagnostiquer une hyperplasie bénigne de la prostate ?\nQuels tests sont utilisés pour évaluer la DHT ?\nQuels symptômes indiquent un besoin d'inhibiteurs ?\nComment évaluer l'efficacité des inhibiteurs ?", "url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteurs de la 5-alpha réductase", "description": "Quels sont les symptômes de l'hyperplasie bénigne de la prostate ?\nLa calvitie est-elle un symptôme lié à la DHT ?\nQuels effets secondaires peuvent survenir ?\nLes inhibiteurs affectent-ils la libido ?", "url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteurs de la 5-alpha réductase", "description": "Peut-on prévenir l'hyperplasie bénigne de la prostate ?\nY a-t-il des mesures préventives pour la calvitie ?\nLes inhibiteurs peuvent-ils être utilisés préventivement ?\nQuels changements de mode de vie sont recommandés ?", "url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteurs de la 5-alpha réductase", "description": "Quels médicaments sont des inhibiteurs de la 5-alpha réductase ?\nComment les inhibiteurs agissent-ils ?\nQuelle est la durée du traitement ?\nLes inhibiteurs sont-ils efficaces pour la calvitie ?", "url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteurs de la 5-alpha réductase", "description": "Quelles complications peuvent survenir avec les inhibiteurs ?\nLes inhibiteurs augmentent-ils le risque de cancer ?\nComment gérer les effets secondaires ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteurs de la 5-alpha réductase", "description": "Quels sont les facteurs de risque de l'hyperplasie bénigne ?\nLa génétique joue-t-elle un rôle dans la calvitie ?\nLe mode de vie influence-t-il la DHT ?\nL'âge est-il un facteur de risque pour la calvitie ?", "url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une hyperplasie bénigne de la prostate ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un examen physique, des tests urinaires et un dosage du PSA aident au diagnostic." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la DHT ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Un dosage sanguin de la DHT peut être effectué pour évaluer les niveaux hormonaux." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin d'inhibiteurs ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes urinaires comme des difficultés à uriner peuvent indiquer un besoin." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité des inhibiteurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par l'amélioration des symptômes et la réduction du PSA." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'hyperplasie bénigne de la prostate ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des mictions fréquentes, un jet urinaire faible et des douleurs." } }, { "@type": "Question", "name": "La calvitie est-elle un symptôme lié à la DHT ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la DHT est impliquée dans la perte de cheveux androgénétique chez les hommes." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent la dysfonction érectile, la réduction de la libido et la gynécomastie." } }, { "@type": "Question", "name": "Les inhibiteurs affectent-ils la libido ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains patients peuvent éprouver une diminution de la libido en raison des inhibiteurs." } }, { "@type": "Question", "name": "Peut-on prévenir l'hyperplasie bénigne de la prostate ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine et un mode de vie actif peuvent aider à réduire le risque." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour la calvitie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des soins capillaires appropriés et des traitements précoces peuvent aider à prévenir la calvitie." } }, { "@type": "Question", "name": "Les inhibiteurs peuvent-ils être utilisés préventivement ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Ils ne sont généralement pas utilisés en prévention, mais pour traiter des symptômes existants." } }, { "@type": "Question", "name": "Quels changements de mode de vie sont recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée, l'exercice régulier et la gestion du stress sont conseillés." } }, { "@type": "Question", "name": "Quels médicaments sont des inhibiteurs de la 5-alpha réductase ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les médicaments comme le finastéride et le dutastéride sont des inhibiteurs connus." } }, { "@type": "Question", "name": "Comment les inhibiteurs agissent-ils ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Ils bloquent la conversion de la testostérone en DHT, réduisant ainsi les symptômes." } }, { "@type": "Question", "name": "Quelle est la durée du traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut durer plusieurs mois avant d'observer des résultats significatifs." } }, { "@type": "Question", "name": "Les inhibiteurs sont-ils efficaces pour la calvitie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent ralentir la perte de cheveux et favoriser la repousse chez certains patients." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les inhibiteurs ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme la dysfonction érectile et des troubles hormonaux peuvent survenir." } }, { "@type": "Question", "name": "Les inhibiteurs augmentent-ils le risque de cancer ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent des résultats contradictoires, mais un suivi médical est recommandé." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Consulter un médecin pour ajuster le traitement ou envisager des alternatives est conseillé." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles après l'arrêt du traitement, mais pas toutes." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de l'hyperplasie bénigne ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, l'obésité et des antécédents familiaux augmentent le risque d'hyperplasie bénigne." } }, { "@type": "Question", "name": "La génétique joue-t-elle un rôle dans la calvitie ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la génétique est un facteur majeur dans la perte de cheveux androgénétique." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il la DHT ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les niveaux de DHT." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour la calvitie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de calvitie augmente avec l'âge, surtout chez les hommes." } } ] } ] }

Sources (10000 au total)

Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.

Bladder cancer (BLCA) is a highly prevalent tumour and a health problem worldwide, especially among men. Recent work has highlighted the relevance of the tumour microenvironment (TME) in cancer biolog... To review the role of CAFs in BLCA biology and provide an understanding of CAF origin, subtypes, markers, and phenotypic and functional characteristics to improve patient management.... A PubMed search was performed to review manuscripts published using the terms "cancer associated fibroblast" and "bladder cancer" or "urothelial cancer". All abstracts were reviewed, and the full cont... CAFs have been studied less extensively in BLCA than in other tumours. Thanks to new techniques, such as single-cell RNA-seq and spatial transcriptomics, it is now possible to accurately map and molec... Current knowledge of BLCA CAFs and the TME is being increasingly applied to improve BLCA therapy. There is a need to acquire a deeper understanding of CAF biology in BLCA.... Tumour cells are surrounded by nontumoural cells that contribute to the determination of the behaviour of cancers. Among them are cancer-associated fibroblasts. The "neighbourhoods" established throug...

Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.

Ovarian cancer (OC) is distinguished by its aggressive nature and the limited efficacy of current treatment strategies. Recent studies have emphasized the significant role of cancer-associated fibrobl... Employing sophisticated machine learning techniques on bulk transcriptomic datasets, we identified fibroblast growth factor 7 (FGF7), derived from CAFs, as a potential oncogenic factor. We investigate... Our findings indicate that higher FGF7 levels correlate with advanced tumor stages, increased vascular invasion, and poorer prognosis. CAFs-derived FGF7 significantly enhanced OC cell proliferation, m... Neutralizing FGF7 in the medium or inhibiting HIF-1α signaling reversed the effects of FGF7-mediated EMT, emphasizing the dependence of FGF7-mediated EMT on HIF-1α activation. These findings suggest t...

Cancer-associated fibroblast-dependent and -independent invasion of gastric cancer cells.

Cancer cells are known to exhibit a cancer-associated fibroblast (CAF)-dependent invasive mode in the presence of CAFs. The purpose of this study was to investigate whether intrinsic factors of gastri... We observed dynamic movement of CAFs, and cancer cells, by time-lapse imaging of 2-D and 3-D collagen invasion models, and evaluated invasion modes of gastric cancer cell lines (MKN-7, MKN-45, and HSC... When MKN-7 and MKN-45 cells were co-cultured with CAFs, CAFs first invade collagen matrix followed by cancer cells (CAF-dependent invasion), whereas HSC44PE cells invaded collagen matrix independent o... These results indicate that in presence of CAFs, gastric cancer cells exhibit both CAF-dependent and -independent modes of invasion, the determinants of which may depend on the intrinsic properties of...